Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells $114,900.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Michael Secora also recently made the following trade(s):

• On Tuesday, October 8th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.32, for a total transaction of $94,800.00.
• On Tuesday, September 10th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.17, for a total transaction of $92,550.00.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX traded down $0.54 during mid-day trading on Friday, hitting $6.37. The company had a trading volume of 2,818,972 shares, compared to its average volume of 5,717,881. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.89 and a 12 month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $1.79 billion, a P/E ratio of -4.18 and a beta of 0.81. The business’s 50-day simple moving average is $6.65 and its 200-day simple moving average is $7.61.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.43) EPS. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RXRX. Janney Montgomery Scott LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $310,000. Swiss National Bank increased its holdings in Recursion Pharmaceuticals by 9.6% during the 1st quarter. Swiss National Bank now owns 308,500 shares of the company’s stock valued at $3,076,000 after purchasing an additional 27,100 shares in the last quarter. Russell Investments Group Ltd. raised its position in Recursion Pharmaceuticals by 45.2% in the 1st quarter. Russell Investments Group Ltd. now owns 158,305 shares of the company’s stock valued at $1,578,000 after purchasing an additional 49,292 shares during the last quarter. ProShare Advisors LLC raised its position in Recursion Pharmaceuticals by 14.1% in the 1st quarter. ProShare Advisors LLC now owns 40,949 shares of the company’s stock valued at $408,000 after purchasing an additional 5,051 shares during the last quarter. Finally, Kingsview Wealth Management LLC acquired a new position in Recursion Pharmaceuticals in the first quarter worth $240,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.